Year All2024202320222021202020192018201720162015201420122011 May 22, 2024 Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference May 21, 2024 Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults May 16, 2024 Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor) May 14, 2024 Ardelyx, Inc. Reports Employment Inducement Grants May 7, 2024 Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference May 2, 2024 Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update May 1, 2024 Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings Apr 18, 2024 Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024 Mar 28, 2024 Ardelyx, Inc. Reports Employment Inducement Grants Mar 25, 2024 Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy